Discover some facts about the biological model C. elegans.
As part of the study, a screening was performed in C. elegans using Nagi Bioscience’s fully automated high-content screening platform in order to determine the efficacy and necessary dosage of the test compounds.
We are proud to announce that Nagi Bioscience has entered the distinguished TOP 100 Swiss Start Up 2022 ranking under the biotech category.
A unique data processing pipeline using a unique AI-based software for C.elegans assays.
The animal testing market loses the battle of growth against non-animal technologies.
We called our SydLab System a high-content screening technology many times, but what does it mean exactly?
Nagi & MolGen in tandem at the European Worm Meeting 2022 at booth #5
Exploring the advantages of microfluidic chips for biological experiments.
The quest for efficiency does not distinguish between industries. And labs are no exception. But, what does it implies to automate your lab?
Our CEO and co-founder, Matteo Cornaglia, speaks today about the future of New Approach Methodologies and how Nagi Bioscience is fulfilling this market need in an interview for Verve Ventures.